Cargando…

Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration

BACKGROUND: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes remains unclear. METHODS: Patients with castrati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dorff, Tanya, Zengin, Zeynep, Henderson, Nicholas, Ali, Alicia, Nguyen, Charles, Hwang, Clara, Barata, Pedro C., Bilen, Mehmet, graham, laura, Mo, George, Kilari, Deepak, Tripathi, Abhishek, Labriola, Matthew, Rothstein, Shoshana, Garje, Rohan, Koshkin, Vadim, Patel, Vaibhav, Schweizer, Michael, Armstrong, Andrew, McKay, Rana, Alva, Ajjai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441451/ https://www.ncbi.nlm.nih.gov/pubmed/37609284 http://dx.doi.org/10.21203/rs.3.rs-3201150/v1

Ejemplares similares

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
por: Hwang, Clara, et al.
Publicado: (2023)

PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
por: Koshkin, Vadim S., et al.
Publicado: (2021)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
por: Barata, Pedro, et al.
Publicado: (2020)

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer()()
por: Qiao, Yuanyuan, et al.
Publicado: (2016)

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
por: Schweizer, Michael T., et al.
Publicado: (2017)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma
por: Nguyen, Charles B., et al.
Publicado: (2022)

Association between diabetes mellitus and poor patient outcomes after out-of-hospital cardiac arrest: A systematic review and meta-analysis
por: Voruganti, Dinesh Chandra, et al.
Publicado: (2018)

CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)
por: Ebrahimi, Hedyeh, et al.
Publicado: (2023)

Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia
por: Alva, Ajjai, et al.
Publicado: (2015)

Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research
por: Koshkin, Vadim S., et al.
Publicado: (2018)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer
por: Dorff, Tanya B, et al.
Publicado: (2018)

Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients
por: Lyou, Yung, et al.
Publicado: (2021)

Cardiovascular Toxicity During Advanced Prostate Cancer Treatment: Minding the Heart
por: Dorff, Tanya, et al.
Publicado: (2023)

$^{43}$Ar and $^{44}$Ar
por: Hudis, J, et al.
Publicado: (1970)

$^{43}Ar$ and $^{44}Ar$
por: Hudis, J, et al.
Publicado: (1970)

To Be(Ar) Or Not to Be(Ar) – Jones Dilemma?
por: Andrews, Nicholas A., et al.
Publicado: (2022)

Ipilimumab induced digital vasculitis
por: Padda, Amrita, et al.
Publicado: (2018)

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials
por: Koshkin, Vadim S., et al.
Publicado: (2018)

LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types
por: Brown, Landon C, et al.
Publicado: (2021)

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
por: Vikas, Praveen, et al.
Publicado: (2020)

Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
por: Meza, Luis, et al.
Publicado: (2023)

Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review
por: Koshkin, Vadim S., et al.
Publicado: (2021)

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
por: Koshkin, Vadim S., et al.
Publicado: (2019)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
por: Garje, Rohan, et al.
Publicado: (2020)

Ár njöt'i ar hai = El color de la tierra
Publicado: (2014)

The mass of $^{32}Ar$ and $^{33}Ar$ for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

Masses of 32Ar and 33Ar for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection
por: Yu, Steven S, et al.
Publicado: (2016)

The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review
por: Martin, Felicity C., et al.
Publicado: (2023)

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022)

Determination of $^{44}Ar$(n,$\gamma$)$^{45}$Ar, and $^{46}$Ar(n,$\gamma$)$^{47}$Ar reaction rates by (d,p) transfer reactions
por: Sorlin, O, et al.
Publicado: (2002)

ARS Leptogenesis
por: Drewes, M., et al.
Publicado: (2017)

Ars melancholiae
por: Weiss, Silvius Leopold, 1686-1750
Publicado: (1994)

Ars Obstetrica
por: Armytage, V. B. Green
Publicado: (1930)

Ars Gynæcologica
por: Green-Armytage, V. B.
Publicado: (1930)

Cannot write session to /tmp/vufind_sessions/sess_a1i9fbi8uofck0u2r2uuot70at